Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
Moodys
Baxter
Colorcon

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Dorzagliatin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Dorzagliatin?

Dorzagliatin is an investigational drug.

There have been 4 clinical trials for Dorzagliatin. The most recent clinical trial was a Phase 1 trial, which was initiated on March 27th 2018.

The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Hua Medicine Limited and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Dorzagliatin
TitleSponsorPhase
Drug Interaction Study Between Dorzagliatin and EmpagliflozinHua Medicine LimitedPhase 1
Drug Interaction Study Between Dorzagliatin and SitagliptinHua Medicine LimitedPhase 1
DDI Study Between Dorzagliatin and RifampicinHua Medicine LimitedPhase 1

See all Dorzagliatin clinical trials

Clinical Trial Summary for Dorzagliatin

Top disease conditions for Dorzagliatin
Top clinical trial sponsors for Dorzagliatin

See all Dorzagliatin clinical trials

US Patents for Dorzagliatin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Dorzagliatin   Start Trial Pyrrolidinone glucokinase activators Hoffmann-La Roche Inc. (Nutley, NJ)   Start Trial
Dorzagliatin   Start Trial Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1H-pyrazol-3-ylamine HUA MEDICINE (Grand Gayman, KY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Dorzagliatin

Drugname Country Document Number Estimated Expiration Related US Patent
Dorzagliatin Argentina 071474 2028-04-16   Start Trial
Dorzagliatin Austria 557017 2028-04-16   Start Trial
Dorzagliatin Australia 2009237794 2028-04-16   Start Trial
Dorzagliatin Brazil PI0911035 2028-04-16   Start Trial
Dorzagliatin Canada 2720524 2028-04-16   Start Trial
Dorzagliatin Chile 2009000889 2028-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Medtronic
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.